Dr. Melanie Linn, DACVR-RO (previously Melanie Moore) at the MSU College of Veterinary Medicine is recruiting patients for a clinical trial that evaluates stereotactic radiation therapy to treat nonsurgical canine hepatocellular carcinomas. The trial offers a substantial financial benefit to clients--it covers most of the cost for radiation and the follow-up visits.

Why is MSU doing this trial?

Supportive care for nonresectable HCCs in dogs has shown a median survival time of 9 months. Case reports and anecdotal evidence for stereotactic radiation to canine HCC suggests long-term control over 18 months with minimal adverse effects.

The goal of this study is to support the preliminary evidence and provide a protocol that can be used without advanced motion monitoring, which is technology that is not widely available in veterinary medicine.

Who is eligible for enrollment?
  • Dogs with a histologic- or cytologic-confirmed hepatocellular carcinoma
    • Cytologic diagnosis is permitted if it provides a definitive diagnosis
    • No diffuse HCC due to lack of discrete target
  • No previous radiation therapy of this tumor
  • Complete blood count (performed within past six weeks)
  • Blood chemistry panel (performed within past six weeks)
  • Thoracic radiographs (or other thoracic imaging, performed within past six weeks)
What will be expected of clients and patients?

Dogs will undergo a specialized planning CT scan of the liver, three stereotactic radiation treatments, and routine rechecks for the first year after radiation. At six months, MSU also will perform a recheck CT scan. All scans and radiation treatments will be done under general anesthesia. Most of these costs will be covered by the trial.

When does trial enrollment open?
  • The trial is enrolling patients now through June 30, 2024.
  • We will notify you if the trial fully enrolls.
How do I enroll a patient?

Please contact Dr. Linn at moore231@msu.edu or the MSU Radiation Oncology Service at cvm.radonc@msu.edu or 517-353-5420.